Paper Details

  1. Home
  2. Paper Details

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab.

Author: ColombelJean Frédéric, FeaganBrian G, HanauerStephen B, HorganKevin, JohannsJewel, LichtensteinGary R, LuJiandong, OlsonAllan, PresentDaniel, RachmilewitzDaniel, ReinischWalter, RutgeertsPaul, SandbornWilliam J, SandsBruce E, de VilliersWillem J S

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study found that infliximab treatment was associated with a lower risk of colectomy in patients with moderately to severely active ulcerative colitis. The cumulative incidence of colectomy was 10% for infliximab and 17% for placebo.
Paper Details　
Original Abstract of the Article :
BACKGROUND & AIMS: The efficacy of infliximab for treating patients with ulcerative colitis has been established. METHODS: The Active Ulcerative Colitis Trial (ACT)-1 and ACT-2 randomized, double-blind, placebo-controlled studies evaluated infliximab induction and maintenance therapy in moderately ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1053/j.gastro.2009.06.061

データ提供：米国国立医学図書館（NLM）

Infliximab: A Beacon of Hope for Ulcerative Colitis

This research sheds light on the efficacy of infliximab in treating patients with moderately to severely active ulcerative colitis. The study compared the outcomes of patients who received infliximab with those who received placebo, uncovering a significant difference in colectomy rates. The authors meticulously analyzed the data to determine the impact of infliximab on colectomy, hospitalization, and other relevant outcomes.

A Shift in the Desert Landscape: Reduced Colectomy Rates

The study revealed a compelling finding: patients treated with infliximab were less likely to undergo colectomy compared to those who received placebo. This observation highlights the potential of infliximab in significantly reducing the risk of major surgery for patients with ulcerative colitis. It's like introducing a new species of plant into a desert ecosystem: infliximab has the potential to alter the natural course of the disease and improve long-term outcomes.

Navigating the Oasis of Ulcerative Colitis

This study underscores the importance of early and effective treatment in managing ulcerative colitis. For patients with this debilitating condition, infliximab offers a glimmer of hope, potentially reducing the need for invasive procedures and improving quality of life. It's like discovering a hidden oasis in the desert: infliximab provides a sanctuary from the harsh realities of the disease.

Dr.Camel's Conclusion

This research highlights the importance of infliximab as a promising treatment for ulcerative colitis, potentially reducing the need for surgery and improving the lives of patients. It serves as a beacon of hope for those navigating the challenging landscape of chronic inflammatory bowel disease.

Date :
  1. Date Completed 2009-10-15
  2. Date Revised 2021-10-18
Further Info :

Pubmed ID

19596014

DOI: Digital Object Identifier

10.1053/j.gastro.2009.06.061

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.